drugset / Trial / NCT02372942
Lactoferrin or Progesterone for Prevention of Preterm Delivery
RandomizedParallel-groupSingle-blindPrevention
Summary
Primary endpoint will be evaluate the effectiveness of vaginal lactoferrin in the reduction of the 30% of preterm deliveries versus the use of progesterone, in specific selected patients, with consequent improvement in neonatal outcome. Secondary endpoint will be compare antibacterial and anti-inflammatory activity of lactoferrin by evaluation of systemic biochemical and urinary markers.
Timeline
- Start
- 2014-02
- Primary completion
- 2019-11
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lactoferrin | Protein / enzyme biologic | 300 mg | Other |
| Subject | Progesterone | Other / unclassified | 200 mg | Other |
Indications
No indication recorded.